vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and POTLATCHDELTIC CORP (PCH). Click either name above to swap in a different company.
POTLATCHDELTIC CORP is the larger business by last-quarter revenue ($314.2M vs $247.1M, roughly 1.3× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 8.2%, a 2.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 23.1%). POTLATCHDELTIC CORP produced more free cash flow last quarter ($50.1M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 11.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
POTLATCHDELTIC CORPPCHEarnings & Financial Report
PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.
ANIP vs PCH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $314.2M |
| Net Profit | $27.5M | $25.9M |
| Gross Margin | — | 18.2% |
| Operating Margin | 14.1% | 11.2% |
| Net Margin | 11.1% | 8.2% |
| Revenue YoY | 29.6% | 23.1% |
| Net Profit YoY | 367.5% | 682.5% |
| EPS (diluted) | $1.14 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $314.2M | ||
| Q2 25 | $211.4M | $275.0M | ||
| Q1 25 | $197.1M | $268.3M | ||
| Q4 24 | $190.6M | $258.1M | ||
| Q3 24 | $148.3M | $255.1M | ||
| Q2 24 | $138.0M | $320.7M | ||
| Q1 24 | $137.4M | $228.1M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $25.9M | ||
| Q2 25 | $8.5M | $7.4M | ||
| Q1 25 | $15.7M | $25.8M | ||
| Q4 24 | $-10.3M | $5.2M | ||
| Q3 24 | $-24.2M | $3.3M | ||
| Q2 24 | $-2.3M | $13.7M | ||
| Q1 24 | $18.2M | $-305.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 13.0% | ||
| Q1 25 | — | 17.8% | ||
| Q4 24 | — | 13.4% | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 11.9% | ||
| Q1 24 | — | 7.0% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 11.2% | ||
| Q2 25 | 6.6% | 5.0% | ||
| Q1 25 | 13.3% | 10.3% | ||
| Q4 24 | -2.3% | 5.2% | ||
| Q3 24 | -13.8% | 2.8% | ||
| Q2 24 | 3.7% | 5.4% | ||
| Q1 24 | 14.8% | -2.1% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 8.2% | ||
| Q2 25 | 4.0% | 2.7% | ||
| Q1 25 | 8.0% | 9.6% | ||
| Q4 24 | -5.4% | 2.0% | ||
| Q3 24 | -16.3% | 1.3% | ||
| Q2 24 | -1.7% | 4.3% | ||
| Q1 24 | 13.2% | -0.1% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $0.33 | ||
| Q2 25 | $0.36 | $0.09 | ||
| Q1 25 | $0.69 | $0.33 | ||
| Q4 24 | $-0.45 | $0.07 | ||
| Q3 24 | $-1.27 | $0.04 | ||
| Q2 24 | $-0.14 | $0.17 | ||
| Q1 24 | $0.82 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $88.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.9B |
| Total Assets | $1.4B | $3.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $88.8M | ||
| Q2 25 | $217.8M | $95.3M | ||
| Q1 25 | $149.8M | $147.5M | ||
| Q4 24 | $144.9M | $151.6M | ||
| Q3 24 | $145.0M | $161.1M | ||
| Q2 24 | $240.1M | $199.7M | ||
| Q1 24 | $228.6M | $180.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $1.9B | ||
| Q2 25 | $436.8M | $1.9B | ||
| Q1 25 | $418.6M | $2.0B | ||
| Q4 24 | $403.7M | $2.0B | ||
| Q3 24 | $405.9M | $2.1B | ||
| Q2 24 | $455.8M | $2.1B | ||
| Q1 24 | $452.0M | $2.2B |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $3.2B | ||
| Q2 25 | $1.3B | $3.2B | ||
| Q1 25 | $1.3B | $3.3B | ||
| Q4 24 | $1.3B | $3.3B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $920.8M | $3.4B | ||
| Q1 24 | $914.5M | $3.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.51× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $65.7M |
| Free Cash FlowOCF − Capex | $29.1M | $50.1M |
| FCF MarginFCF / Revenue | 11.8% | 15.9% |
| Capex IntensityCapex / Revenue | 0.5% | 4.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.54× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $132.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $65.7M | ||
| Q2 25 | $75.8M | $41.0M | ||
| Q1 25 | $35.0M | $49.1M | ||
| Q4 24 | $15.9M | $45.4M | ||
| Q3 24 | $12.5M | $26.5M | ||
| Q2 24 | $17.4M | $100.6M | ||
| Q1 24 | $18.3M | $16.0M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $50.1M | ||
| Q2 25 | $71.8M | $30.6M | ||
| Q1 25 | $32.5M | $26.3M | ||
| Q4 24 | $13.5M | $25.4M | ||
| Q3 24 | $7.7M | $-8.2M | ||
| Q2 24 | $13.0M | $72.4M | ||
| Q1 24 | $13.7M | $2.0M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 15.9% | ||
| Q2 25 | 34.0% | 11.1% | ||
| Q1 25 | 16.5% | 9.8% | ||
| Q4 24 | 7.1% | 9.9% | ||
| Q3 24 | 5.2% | -3.2% | ||
| Q2 24 | 9.4% | 22.6% | ||
| Q1 24 | 10.0% | 0.9% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 4.9% | ||
| Q2 25 | 1.9% | 3.8% | ||
| Q1 25 | 1.3% | 8.5% | ||
| Q4 24 | 1.3% | 7.7% | ||
| Q3 24 | 3.2% | 13.6% | ||
| Q2 24 | 3.2% | 8.8% | ||
| Q1 24 | 3.3% | 6.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 2.54× | ||
| Q2 25 | 8.87× | 5.58× | ||
| Q1 25 | 2.23× | 1.90× | ||
| Q4 24 | — | 8.74× | ||
| Q3 24 | — | 7.99× | ||
| Q2 24 | — | 7.35× | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PCH
| Lumber | $131.8M | 42% |
| Timberlands | $52.5M | 17% |
| Rural Real Estate | $51.3M | 16% |
| Residuals And Panels | $34.0M | 11% |
| Pulpwood | $16.7M | 5% |
| Development Real Estate | $14.6M | 5% |
| Other | $8.1M | 3% |
| Other Products | $5.2M | 2% |
